SPY295.44+0.56 0.19%
DIA244.88-0.14 -0.06%
IXIC9,324.59+39.71 0.43%

Biocryst Pharmaceuticals Q4 EPS $(0.02) Beats $(0.26) Estimate, Sales $39.725M Beat $9.88M Estimate

Biocryst Pharmaceuticals (NASDAQ:BCRX) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.26) by 92.31 percent. This is a 92 percent increase over losses of $(0.25) per share

Benzinga · 03/05/2020 12:35

Biocryst Pharmaceuticals (NASDAQ:BCRX) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.26) by 92.31 percent. This is a 92 percent increase over losses of $(0.25) per share from the same period last year. The company reported quarterly sales of $39.725 million which beat the analyst consensus estimate of $9.88 million by 302.07 percent. This is a 1.36K percent increase over sales of $2.729 million the same period last year.